Ocata Therapeutics to Present at 17th Annual BIO CEO & Investor Conference
February 04 2015 - 9:12AM
Business Wire
Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), a leader in the
field of regenerative ophthalmology, today announced that Paul
Wotton, Ph.D., President and Chief Executive Officer, will present
a company overview at the 17th Annual BIO CEO and Investor
Conference on Monday, February 9, 2015 at 9:30 a.m. ET in New York
City.
A live audio webcast of the presentation will be available via
the "Investor Relations" page of the Ocata website, www.ocata.com.
A replay of the webcast will be archived on Ocata's website for 90
days following the presentation.
About Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. is a clinical stage biotechnology
company focused on the development and commercialization of
regenerative ophthalmology therapeutics. Ocata’s most advanced
products are in clinical trials for the treatment of Stargardt’s
macular degeneration, dry age-related macular degeneration, and
myopic macular degeneration. Ocata’s intellectual property
portfolio includes pluripotent stem cell platforms – hESC and
induced pluripotent stem cell (iPSC) – and other cell therapy
research programs. For more information, visit www.ocata.com.
Investors:Westwicke PartnersJohn Woolford,
443-213-0506john.woolford@westwicke.comorPress:Russo PartnersDavid
Schull, 858-717-2310david.schull@russopartnersllc.com
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ocata Therapeutics, Inc. (NASDAQ:OCAT)
Historical Stock Chart
From Sep 2023 to Sep 2024